Gilead will test remdesivir in children with COVID-19

Gilead Sciences has said it will start trials soon of its antiviral drug remdesivir in children – from newborns to adolescents – who have moderate-to-severe COVID-19.

Gilead files remdesivir for EU approval, with a verdict poss...

The EMA has said it will fast-track the review of Gilead Sciences’ remdesivir as a treatment for COVID-19, after the US biopharma submitted its marketing application for the dr

AstraZeneca ‘probably couldn’t run Gilead any better:’ analy...

AstraZeneca and Gilead are both staying tight-lipped over rumoured merger talks, but the consensus among analysts seems to be that there would anyway be little value in such a

New remdesivir study leaves clinicians guessing about its ef...

The latest tranche of data with Gilead Sciences’ remdesivir in COVID-19 patients isn’t making it easy to gauge how well it is working.

Gilead trumpets data with newly-bought magrolimab in blood c...

Just three months after acquiring Forty Seven for $4.9 billion, Gilead has reported positive data on magrolimab, the lead drug from the deal, at ASCO 2020.

Gilead slides as second Chinese trial of remdesivir is stopp...